UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
(Mark One)
|X| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1999
-------------------------------------------------
OR
|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ______________________ to ______________________
Commission file number 0-26206
---------------------------------------------------------
Norland Medical Systems, Inc.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 06-1387931
- --------------------------------- -------------------
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
106 Corporate Park Drive, Suite 106
White Plains, New York 10604
- --------------------------------------------------------------------------------
(Address of principal executive offices)
(Zip Code)
(914) 694-2285
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
- --------------------------------------------------------------------------------
(Former name, former address and former fiscal year, if changed since last
report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes |X| No |_|
As of May 10, 1999, 18,752,500 shares of the registrant's Common Stock,
$0.0005 par value, were outstanding.
-1-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
TABLE OF CONTENTS FOR FORM 10-Q
Page
----
Title Page....................................................................1
Document Table of Contents....................................................2
Introduction..................................................................3
PART I FINANCIAL INFORMATION.................................................4
Item 1. Condensed Consolidated Financial Statements...........................4
Condensed Consolidated Balance Sheets.................................4
Condensed Consolidated Statements of Operations.......................5
Condensed Consolidated Statements of Cash Flows.......................6
Notes to Condensed Consolidated Financial Statements..................7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations.............................................9
Item 3. Quantitative and Qualitative Disclosures About Market Risks..........13
PART II OTHER INFORMATION....................................................14
Item 1. Legal Proceedings....................................................14
Item 2. Changes in Securities................................................14
Item 3. Defaults Upon Senior Securities......................................14
Item 4. Submission of Matters to a Vote of Security Holders..................14
Item 5. Other Information....................................................14
Item 6. Exhibits and Reports on Form 8-K.....................................15
Signatures...................................................................16
Exhibit Index................................................................17
-2-
<PAGE>
Norland Medical Systems, Inc.
INTRODUCTION
The statements included in this Report regarding future financial performance
and results and the other statements that are not historical facts are
forward-looking statements. The words "believes," "intends," "expects,"
"anticipates," "projects," "estimates," "predicts," and similar expressions are
also intended to identify forward-looking statements. These forward-looking
statements are based on current expectations and are subject to risks and
uncertainties. In connection with the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, the Company cautions the reader that
actual results or events could differ materially from those set forth or implied
by the forward-looking statements and related assumptions due to certain
important factors, including, without limitation, the following: (i) the
continued development of new products and product enhancements that can be
marketed by the Company; (ii) the importance to the Company's sales growth that
the efficacy of new therapies for the treatment of osteoporosis and other bone
disorders be demonstrated and that regulatory approval of such therapies be
granted, particularly in the United States; (iii) the acceptance and adoption by
primary care providers of new osteoporosis therapies and the Company's ability
to expand sales of its products to these physicians; (iv) the Company may be
adversely affected by changes in the reimbursement policies of governmental
programs (e.g., Medicare and Medicaid) and private third party payors, including
private insurance plans and managed care plans; (v) the high level of
competition in the bone densitometry market; (vi) changes in bone densitometry
technology; (vii) the Company's ability to continue to maintain and expand
acceptable relationships with third party dealers and distributors; (viii) the
Company's ability to provide attractive financing options to its customers and
to provide customers with fast and efficient service for the Company's products;
(ix) changes that may result from health care reform in the United States may
adversely affect the Company; (x) the Company's cash flow and the results of its
ongoing financing efforts; (xi) the effect of regulation by the United States
Food and Drug Administration and other agencies; (xii) the effect of the
Company's accounting policies; (xiii) the outcome of pending litigation; (xiv)
potential Year 2000 compliance problems affecting the Company and third parties
with whom it deals; and (xv) other risks described elsewhere in this Report and
in other documents filed by the Company with the Securities and Exchange
Commission. The Company is also subject to general business risks, including
adverse state, federal or foreign legislation and regulation, adverse publicity
or news coverage, changes in general economic factors and the Company's ability
to retain and attract key employees. Nothing contained in the Report should be
viewed as suggesting the existence of a trend or protection of any future trend
with respect to any matter. Any forward-looking statements included in this
Report are made as of the date hereof, based on information available to the
Company as of the date hereof, and the Company assumes no obligation to update
any forward-looking statements.
-3-
<PAGE>
Norland Medical Systems, Inc.
PART I FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
Norland Medical Systems, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
<TABLE>
<CAPTION>
March 31, 1999 December 31, 1998
-------------- -----------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 915,373 $ 1,105,140
Accounts receivable - trade, less allowance for
doubtful accounts of $330,000 at March 31, 1999
and December 31, 1998 2,537,903 1,877,271
Income taxes receivable -- 340,000
Inventories, net 1,885,627 2,521,345
Prepaid expenses and other current assets 244,092 187,354
Deferred income taxes 1,858,217 1,817,217
------------ ------------
Total current assets 7,441,212 7,848,327
------------ ------------
Officer's loan receivable 92,488 91,304
Property and equipment, net 1,367,447 1,392,032
Deferred income taxes, net 2,111,624 1,575,624
Goodwill, net 8,001,856 8,150,620
------------ ------------
Total assets $ 19,014,627 $ 19,057,907
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - related parties $ 322,302 $ 292,315
Accounts payable - trade 1,725,748 1,435,616
Accrued expenses 2,476,200 2,215,219
Accrued warranty expenses 956,000 920,000
Accrued interest expense 378,829 577,184
------------ ------------
Total current liabilities 5,859,079 5,440,334
------------ ------------
Note payable, net of discount 1,066,719 4,685,690
Other -- 140,000
Stockholders' equity:
Common stock and additional paid-in capital 37,055,254 33,143,424
Accumulated deficit (24,966,425) (24,351,541)
------------ ------------
Total stockholders' equity 12,088,829 8,791,883
------------ ------------
Total liabilities and stockholders' equity $ 19,014,627 $ 19,057,907
============ ============
</TABLE>
See accompanying notes to condensed consolidated financial statements.
-4-
<PAGE>
Norland Medical Systems, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
For the Three Months Ended
---------------------------------
March 31, 1999 March 31, 1998
-------------- --------------
Revenue $ 4,825,934 $ 2,062,707
Cost of revenue 2,531,898 1,805,914
------------ -----------
Gross profit 2,294,036 256,793
Sales and marketing expense 1,434,997 1,664,575
General and administrative expense 944,821 1,037,809
Research and development expense 394,126 419,842
------------ -----------
Operating loss (479,908) (2,865,433)
Interest expense (145,005) (318,018)
Interest income 10,029 43,869
------------ -----------
Loss before income taxes (614,884) (3,139,582)
Income tax benefit -- (1,250,000)
------------ -----------
Net loss $ (614,884) $(1,889,582)
------------ -----------
Basic and diluted weighted average shares 14,265,997 7,163,314
Basic and diluted loss per share $ (0.04) $ (0.26)
See accompanying notes to condensed consolidated financial statements.
-5-
<PAGE>
Norland Medical Systems, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
<TABLE>
<CAPTION>
For the Three Months Ended
--------------------------------
March 31, 1999 March 31, 1998
-------------- --------------
<S> <C> <C>
Cash flows from operating activities:
Net loss $ (614,884) $(1,889,582)
Adjustments to reconcile net loss to net cash
used in operating activities:
Amortization expense 204,623 190,206
Depreciation expense 138,346 67,854
Inventory obsolescence expense (credit) (191,780) 325,000
Deferred income taxes -- (1,250,000)
Provision for doubtful accounts 20,077 --
Changes in assets and liabilities:
Accounts receivable (680,709) 1,937,789
Inventories 827,498 (1,039,932)
Prepaid expenses and other current assets (56,738) (2,858)
Accounts payable 320,119 (649,459)
Accrued expenses (41,374) 247,075
Income taxes receivable -- 920,806
Customer deposits -- (375,000)
----------- -----------
Total adjustments 540,062 371,481
----------- -----------
Net cash used in operating activities (74,822) (1,518,101)
----------- -----------
Cash flows from investing activities:
Purchase of property and equipment (113,761) (113,730)
Other (1,184) (1,183)
----------- -----------
Net cash used in investing activities (114,945) (114,913)
----------- -----------
Net decrease in cash (189,767) (1,633,014)
Cash and cash equivalents at beginning of period 1,105,140 3,082,202
----------- -----------
Cash and cash equivalents at end of period $ 915,373 $ 1,449,188
=========== ===========
</TABLE>
Noncash operating, investing and financial activities:
In March 1999, income taxes receivable of $340,000 were reclassified as deferred
income taxes.
In March 1999, the Company elected to pay $4,310,000 of Note principal by the
issuance of 11,122,580 shares of its Common Stock. See Notes 2 and 3.
See accompanying notes to condensed consolidated financial statements.
-6-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(1) BASIS OF PRESENTATION
The condensed consolidated financial statements of Norland Medical Systems, Inc.
(the "Company") presented herein, have been prepared pursuant to the rules of
the Securities and Exchange Commission for quarterly reports on Form 10-Q and do
not include all of the information and footnote disclosures required by
generally accepted accounting principles. These statements should be read in
conjunction with the audited financial statements and notes thereto for the year
ended December 31, 1998, and included in the Company's Form 10-K as filed with
the Securities and Exchange Commission on March 31, 1999.
The condensed consolidated financial statements included herein are unaudited
but, in the opinion of management, include all adjustments (consisting of
normal, recurring adjustments) necessary for a fair presentation of the
financial position, results of operations and cash flows for these interim
periods.
The results of operations for the three months ended March 31, 1999 are not
necessarily indicative of the results to be expected for the entire fiscal year
ending December 31, 1999.
(2) NOTE PAYABLE
As part of the original consideration paid by the Company to Norland Medical
Systems B.V. ("NMS BV") for the acquisition of Norland Corporation ("Norland
Corp.") in September of 1997, the Company issued a $16,250,000 note ("Note")
bearing interest at the rate of 7% per annum. Effective as of December 31, 1998,
the terms of the Norland Corp. acquisition were amended. The purchase price was
lowered by reducing the principal amount of the Note by $8,800,000 to
$7,450,000. In addition, the interest rate was reduced to 6.5%. Also on December
31, 1998, the Company paid $1,890,000 of the reduced principal amount by issuing
7,000,000 shares of its Common Stock to NMS BV, in accordance with provisions of
the Note that allowed the Company to pay principal in shares of its Common
Stock. The principal amount of the Note outstanding after such payment was
$5,560,000. In March 1999, the Company elected to pay an additional $4,310,000
of Note principal by the issuance of 11,122,580 shares of its Common Stock. The
Company issued 4,588,469 of these shares in March. Issuance of remaining
6,534,111 shares is subject to approval, at the June 2, 1999 annual meeting of
stockholders, of a proposed amendment to the Company's Certificate of
Incorporation increasing the number of authorized shares of Common Stock.
The remaining $1,250,000 principal amount of the Note is subject to prepayment
at such time as the Company receives at least $2,000,000 in proceeds from an
equity financing. The Note has a maturity date of September 11, 2002, subject to
the Company's right to extend such maturity date by up to two years (at
increasing interest rates). NMS BV has transferred $1,159,719 in principal
amount of the Note to former stockholders of NMS BV and holds the remaining
$90,281 in Note principal.
-7-
<PAGE>
Norland Medical Systems, Inc.
Notes to Condensed Consolidated Financial Statements (continued):
(Unaudited)
(3) STOCKHOLDERS' EQUITY
As of March 31, 1999, the Company had 20,000,000 shares of authorized Common
Stock and 18,752,500 issued and outstanding. The Company has proposed to
increase to 45,000,000 the number of authorized shares of Common Stock. If the
proposed increase is approved, the Company will issue an additional 6,534,111
shares (See Note 2), as a result of which a total of 25,286,611 shares of Common
Stock will be outstanding.
(4) INVENTORIES
As of March 31, 1999 and December 31, 1998 inventories consisted of the
following:
March 31,1999 December 31, 1998
------------- -----------------
Raw materials, product kits,
spare parts and
sub-assemblies $ 1,934,728 $ 2,322,744
Work in progress 307,618 380,835
Finished goods 856,817 1,151,302
Rental systems 66,464 66,464
Inventory reserve (1,280,000) (1,400,000)
----------- -----------
$ 1,885,627 $ 2,521,345
=========== ===========
-8-
<PAGE>
Norland Medical Systems, Inc.
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
The following discussion of the financial condition and results of operations of
the Company should be read in conjunction with the Consolidated Financial
Statements and related notes thereto included in Item 1 of this Report. The
following discussion contains forward-looking statements which involve risks and
uncertainties, some of which are described in the Introduction to this Report.
The Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of certain factors, including those
discussed in the Introduction.
RESULTS OF OPERATIONS
Revenue for the three months ended March 31, 1999 increased $2,763,227 (134.0%)
to $4,825,934 from $2,062,707 for the comparable period of 1998. The increase in
sales was largely a result of significantly increased sales of its DXA-based
systems in the United States. Sales in the United States and Pacific Rim
represented 75.2% and 11.1%, respectively, of total revenue for the three months
ended March 31, 1999 and 60.8% and 13.1%, respectively, of total revenue for the
three months ended March 31, 1998. Sales of complete bone densitometry systems
represented 89.1% and 86.1% of total revenue for the three months ended March
31, 1999 and 1998, respectively. Sales of parts and services and rental income
comprised the balance of revenues for such periods.
Sales in the United States have been affected by changes in the Medicare
reimbursement rates for bone densitometry tests. In November 1996 the Health
Care Financing Administration (HCFA) announced changes for 1997 that
significantly reduced the reimbursement rate for peripheral bone densitometry
tests. In June 1997 HCFA published proposed changes for 1998 that would have
increased the reimbursement rate for peripheral systems and significantly
reduced the rate for central systems. These proposed reimbursement rates for
1998 were not adopted by HCFA. Instead, the 1998 rates for both peripheral and
central systems, as finally adopted, were increased slightly over their
applicable rates for 1997. Such reimbursement rates are subject to further
changes. Several regional Medicare carriers did not allow any reimbursement for
peripheral bone densitometry tests. However, effective July 1, 1998, HCFA
national policy mandates Medicare coverage of bone density diagnostic tests for
qualified individuals. Revenues and the mix of products sold are expected to
continue to be influenced by the relative degree of difference in reimbursement
rate levels for peripheral and central systems. They will also be influenced by
the Company's ability to bring to the market systems that can be operated more
profitably by end users at the applicable reimbursement levels.
Cost of revenue as a percentage of revenue was 52.5% and 87.6% for the three
months ended March 31, 1999 and 1998, respectively, resulting in a gross margin
of 47.5% for the three months ended March 31, 1999 compared to 12.4% for the
comparable period of 1998. The gross margin for the first quarter of 1999 was
benefited by a $191,780 inventory obsolescence credit and by $240,000 in sales
of refurbished demonstration systems, which had been carried at relatively low
costs. The gross margin for the first quarter of 1998 was adversely affected by
a $325,000 charge for an increased inventory reserve. In addition, because
Norland Corp. has certain fixed manufacturing
-9-
<PAGE>
Norland Medical Systems, Inc.
Results of Operations (continued):
costs each quarter, to the extent that revenues are lower, such fixed costs have
a more negative impact on gross margins.
Sales and marketing expense decreased $229,578 (13.8%) to $1,434,997 for the
three months ended March 31, 1999 from $1,664,575 for the three months ended
March 31, 1998, and decreased as a percentage of revenue to 29.7% from 80.7%.
The dollar decrease was primarily due to decreased advertising and marketing
promotion expenses and travel related expenses incurred by sales and customer
service personnel.
General and administrative expense decreased $92,988 (9.0%) to $944,821 for the
three months ended March 31, 1999 from $1,037,809 for the three months ended
March 31, 1998 and decreased as a percentage of revenue to 19.6% from 50.3%. The
decrease was primarily due to decreased bad debt expense as a result of improved
credit and collections management.
Research and development expense decreased $25,716 (6.1%) to $394,126 for the
three months ended March 31, 1999 from $419,842 for the three months ended March
31, 1998, and also decreased as a percentage of revenue to 8.2% from 20.4%.
The decreases in expenses as a percentage of revenues referred to in the three
preceding paragraphs are also attributable to the Company's increased revenue
for the three-month period ended March 31, 1999 as compared to March 31, 1998.
Interest expense decreased $173,013 (54.4%) to $145,005 for the three months
ended March 31, 1999 from $318,018 for the three months ended March 31, 1998.
Interest expense for both periods represents interest on the Note payable issued
by the Company in connection with the acquisition of Norland Corporation on
September 11, 1997. The decrease in interest expense reflects the reduced
outstanding principal balance of the Note payable. Interest income in the
three-month periods ended March 31, 1999 and 1998 consisted primarily of
interest earned on the Company's cash balances, reduced by other expenses
consisting primarily of bank charges and other fees related to bank transfers.
The decrease in interest income in the three-month period ended March 31, 1999
as compared to March 31, 1998 reflects reduced interest income resulting from
the Company's reduced cash position.
For the quarter ended March 31, 1999 the Company did not recognize a benefit for
income taxes on the loss before income taxes. The Company recognized a benefit
for income taxes as a percentage of the loss before income taxes of 39.8% for
the same period in 1998. Management believes that, based on the Company's
history of operating earnings, exclusive of nonrecurring charges in 1997 and
1998 and its expected income, it is more likely than not that future levels of
income will be sufficient to realize all deferred tax assets, net of the
valuation reserve.
The Company had a net loss of $614,884 ($0.04 per share based on 14,265,997
weighted average shares) for the three months ended March 31, 1999 compared to a
net loss of $1,889,582 ($0.26 per share based on 7,163,314 weighted average
shares) for the three months ended March 31, 1998. The reduction in net loss was
due primarily to the factors discussed above.
-10-
<PAGE>
Norland Medical Systems, Inc.
Results of Operations (continued):
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 1998, the Company had cash of $1,105,140. At March 31, 1999, the
Company had cash of $915,373. The decrease in cash was primarily the result of
the payment of operating expenses, increased accounts receivable and capital
expenditures partially offset by decreased inventories and increased accounts
payable.
At the present time, capital expenditures for the balance of 1999 are estimated
to be $250,000, and include additional demonstration systems, tooling and
continued upgrading of the Company's management information system.
The Company's accounts receivable increased $660,632 (35.2%) to $2,537,903 at
March 31, 1999 from $1,877,271 at December 31, 1998, reflecting the higher
revenues for the quarter.
The Company believes that its current cash position, together with cash flow
from operations, will be adequate to fund the Company's operations at least
through December 31, 1999. In order to increase its cash flow, the Company is
continuing its efforts to stimulate sales and reduce inventory levels. The
Company will be required to use working capital to manufacture the recently
introduced Apollo DXA and Excell. The Company is also continuing to focus its
efforts on maintaining the improvements in the aging of its accounts receivable.
To do so, the Company has implemented higher credit standards for its customers
and is emphasizing the receipt of down payments from customers at the time their
purchase orders are received. The Company is also continuing to be more
aggressive in seeking to collect outstanding receivables.
The Company has been seeking debt and equity financing. The Company does not
have a commitment for such financing, and there can be no guarantee that the
Company will be able to obtain such financing. The failure to do so could
materially adversely affect the Company and its operations. In addition, the
nature of the Company's business is such that it is subject to changes in
technology, government approval and regulation, and changes in third-party
reimbursement in the United States and numerous foreign markets. Significant
changes in one or more of these factors in a major market for the Company's
products could significantly affect the Company's cash needs.
YEAR 2000 READINESS
The year 2000 (Y2K) problem stems from the fact that many existing computer
programs use only the last two digits to refer to a year. As a result, such
programs do not recognize a year that begins with "20" instead of "19", and may
recognize a date using "00" as the year 1900 rather than the year 2000. If not
corrected, many computer applications could fail or produce erroneous results,
such as a temporary inability to process transactions, send invoices or engage
in many ordinary business activities. The Company is evaluating the Y2K problem
with respect to the Y2K readiness of its internal management information and
non-financial systems and the Company's product lines and suppliers. At this
point in time, the Company is not aware of any Y2K problems that are reasonably
likely to have a material effect on the Company's business, results of
operations or financial condition.
The Company is completing its review of its internal management systems for Y2K
compliance. The Company believes that, with the following exceptions, its
information systems are Y2K compliant.
-11-
<PAGE>
Norland Medical Systems, Inc.
Results of Operations (continued):
The Norland Corp. management information systems, as was planned following the
Company's September 1997 acquisition of Norland Corp., are being replaced with
systems that are compatible with the Company's Y2K compliant management
information systems.
The Company has identified certain other application hardware and software which
are not yet Y2K compliant. Upgrades for most of these systems are available as
part of an annual maintenance program. The Company believes that it already has
obtained and installed most of the necessary upgrades for these programs and
that the remaining upgrades will be available during 1999 without material
expense to the Company. The Company anticipates that it will be able to
complete, test and implement all software upgrades that may be material to its
business on a timely basis. There is always a risk that, if the Company has not
properly identified all Y2K compliance issues with respect to its internal
systems, the Company may not be able to implement all necessary changes to these
systems on a timely basis and within budget. This in turn could cause a material
disruption to the Company's business, including the inability to process orders
on a timely basis, which could have a material adverse effect on its business,
results of operations and financial condition.
The Company has evaluated the product lines currently offered by the Company for
Y2K compliance. The Company believes that its peripheral and traditional
DXA-based products are Y2K compliant. With respect to its pQCT and ultrasound
products, certain Y2K compliance issues exist. The Company plans to make
software upgrades for these products available to its customers before January
1, 2000. The costs to the Company, if any, are not expected to be material, as
such upgrades to products still under warranty should be provided by the product
manufacturers at no charge. Upgrades of non-warranty products will be provided
at the customer's expense. The Company has also identified certain older DXA,
SXA and pQCT products that will also require computer hardware and/or software
upgrades to become Y2K compliant. The Company plans to offer users of these
products the opportunity to purchase upgrade options.
The Company's ability to manufacture and sell systems on a timely basis could be
adversely affected by Y2K compliance problems that may be experienced by its
suppliers and customers. The Company has made inquiries of its major suppliers
in an effort to determine their year 2000 readiness. The Company cannot
presently estimate the nature or extent of any potential adverse impact
resulting from the failure of these third parties to achieve Y2K compliance.
Even if such third parties are themselves Y2K compliant, they may be adversely
affected by Y2K problems of third parties with whom they deal.
In addition to the actions described above, at the present time the Company does
not have a contingency plan to address the Y2K problem. The Company is
developing contingency plans to address potential Y2K problems affecting it and
third parties with whom it deals. The Company presently anticipates completing
such plans over the next five months. Should any significant Y2K problems arise
that are not adequately dealt with in such plan, the Company and its business,
financial condition and results of operations could be materially adversely
affected. If the Company does not identify and effectively deal with material
Y2K problems affecting the Company or third parties, the most reasonably likely
worst case scenario would be a systemic failure beyond the control of the
Company, such as a prolonged telecommunications or electrical failure, or a
general disruption of business activities that triggers a significant economic
downturn. The Company believes that the primary business risks to the Company in
such event would include, but not be limited to, loss of
-12-
<PAGE>
Norland Medical Systems, Inc.
Results of Operations (continued):
orders, increased operating costs, inability to obtain inventory on a timely
basis, disruptions in product shipments, or other business interruptions of a
material nature, as well as claims of mismanagement, misrepresentation, or
breach of contract, any of which could have a material adverse effect on the
Company and its business, results of operations and financial condition.
FORWARD-LOOKING STATEMENTS
As indicated in the Introduction to this Report, forward-looking statements,
including those contained in this Management's Discussion and Analysis section,
are subject to risks and uncertainties. This section includes forward-looking
statements with respect to the effect of reimbursement rates on future sales and
product mix, the Company's ability to realize deferred tax assets as recorded,
future capital expenditures, Year 2000 readiness and the Company's plans for
funding its ongoing operations. Such forward-looking statements are subject to
the factors cited in the Introduction.
Item 3. Quantitative and Qualitative Disclosures About Market Risks
The table below provides information about the Company's market sensitive
financial instruments and constitutes a "forward-looking statement". The
Company's major financial market risk exposure is changing interest rates,
primarily in the Unites States. The Company's policy has been to manage its
interest rate risks through use of a fixed rate debt. See Note 3 for a
description of the Note payable. All items described are non-trading and are
stated in U.S. dollars.
<TABLE>
<CAPTION>
Expected Maturity Dates Fair Value
----------------------------------------------------- March 31,
1999 2001 2002 2003 Thereafter Total 1999
---- ---- ---- ---- ---------- ----- ----
<S> <C> <C> <C> <C> <C> <C> <C>
Cash And Cash Equivalents
Bank deposits-non interest
bearing $ 36,529 $ 36,529 $ 36,529
Money Market Mutual Fund Shares $878,844 $ 878,844 $ 878,844
Average interest rate 4.57%
Note Payable
Fixed interest rate - 6.5% $1,250,000 $1,250,000 $1,066,719
</TABLE>
-13-
<PAGE>
Norland Medical Systems, Inc.
PART II OTHER INFORMATION
Item 1. Legal Proceedings
Irwin I. Miller v. Reynald G. Bonmati et al., Defendants, and Norland Medical
Systems, Inc., Nominal Defendant. As indicated in the Company's Annual Report on
Form 10-K for the year ended December 31, 1998, at a hearing held on March 18,
1999, the Court of Chancery of the State of Delaware, New Castle County, signed
an order approving a Stipulation of Settlement with respect to this action. The
Court's order has become final.
Wesley D. Johnson and Pamela S. T. Johnson v. Reynald G. Bonmati, Kurt W.
Streams and Norland Medical Systems, Inc. This shareholder's class action was
filed in the United States District Court for the Southern District of New York
on April 12, 1998 against the Company, Reynald G. Bonmati, its Chief Executive
Officer, and Kurt W. Streams, its Chief Financial Officer. The complaint made
claims under Sections 10(b) and 20 of the Securities Exchange Act of 1934,
arising from the Company's announcement on March 16, 1998 that it would be
restating its financial statements with respect to the fourth quarter of 1996,
and the first three quarters of 1997. Pursuant to an amended complaint filed on
August 10,1998, the claims are made on behalf of a purported class of certain
persons who purchased the Company's Common Stock from February 25, 1997 through
March 31, 1998. Plaintiffs seek compensatory damages in an unspecified amount,
together with prejudgement interest, costs and expenses (including attorneys'
fees and disbursements). The defendants filed a motion to dismiss the amended
complaint. By Order dated April 6, 1999, the motion to dismiss was denied. On
April 30, 1999, defendants filed an answer to the amended complaint, denying all
substantive allegations. No discovery has yet occurred.
In addition, in the normal course of business, the Company is named in lawsuits
in which claims are asserted against the Company. In the opinion of management,
the liabilities, if any, which may ultimately result from such lawsuits are not
expected to have a material adverse effect on the financial position, results of
operations or cash flows of the Company.
Item 2. Change in Securities
None
Item 3. Defaults Upon Senior Securities
None
Item 4. Submission of Matters to a Vote of Security Holders
None
Item 5. Other Information
None
-14-
<PAGE>
Norland Medical Systems, Inc.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits furnished:
27 Financial Data Schedule
(b) Reports on Form 8-K:
The Company filed a Report on form 8-K on January 5, 1999 Reporting
(i) the agreement to settle the Delaware litigation relating to the
acquisition of Norland Corp. and (ii) the reduction in the purchase
price for Norland Corp.
The Company filed a Report on Form 8-K on April 5, 1999 the
Company's payment of $4.31 million in principal of its Note payable
by the issuance of shares of the Company's Common Stock.
-15-
<PAGE>
Norland Medical Systems, Inc.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
NORLAND MEDICAL SYSTEMS, INC.
(Registrant)
Date: May 12, 1999 /s/ Reynald G. Bonmati
---------------------------------------
Reynald G. Bonmati
President
Date: May 12, 1999 /s/ Kurt W. Streams
---------------------------------------
Kurt W. Streams
Vice President, Finance
(Principal Financial and Accounting Officer)
-16-
<PAGE>
Norland Medical Systems, Inc.
Exhibit Index
Number Description
- ------ -----------
27 Financial Data Schedule
-17-
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Condensed Financial Statements and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-END> MAR-31-1999
<CASH> 915,373
<SECURITIES> 0
<RECEIVABLES> 2,837,903
<ALLOWANCES> 330,000
<INVENTORY> 1,885,627
<CURRENT-ASSETS> 7,441,212
<PP&E> 3,408,580
<DEPRECIATION> 2,041,133
<TOTAL-ASSETS> 19,014,627
<CURRENT-LIABILITIES> 5,859,079
<BONDS> 1,066,719
0
0
<COMMON> 9,376
<OTHER-SE> 12,079,453
<TOTAL-LIABILITY-AND-EQUITY> 19,014,627
<SALES> 4,657,254
<TOTAL-REVENUES> 4,825,934
<CGS> 2,531,898
<TOTAL-COSTS> 2,531,898
<OTHER-EXPENSES> 2,773,994
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 145,005
<INCOME-PRETAX> (614,884)
<INCOME-TAX> 0
<INCOME-CONTINUING> (614,884)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (614,884)
<EPS-PRIMARY> 14,265,997
<EPS-DILUTED> 14,265,997
</TABLE>
